Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice

Molecular Nutrition and Food Research

Volumn 56, Issue 9, 2012, Pages 1433-1444

  Shi, Yun Wei ^a   Wang, Cai Ping ^a   Liu, Lei ^a   Liu, Yang Liu ^a   Wang, Xing ^a   Hong, Ye ^a   Li, Zhen ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Gout; Hypouricemic effect; Nephroprotection; Stilbenes; Structure activity relationship

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, MOUSE; ANTIGOUT AGENT; CARRIER PROTEIN; COMBRETASTATIN A4 PHOSPHATE; CREATININE; DISACCHARIDE; GLUCOSE TRANSPORTER; GLUCOSIDE; MEMBRANE PROTEIN; MULBERROSIDE A; OCTAMER TRANSCRIPTION FACTOR 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER; OTERACIL; OTERACIL POTASSIUM; POLYDATIN; POU2F1 PROTEIN, MOUSE; PTEROSTILBENE; RESVERATROL; SLC22A12 PROTEIN, MOUSE; SLC22A2 PROTEIN, MOUSE; SLC22A4 PROTEIN, MOUSE; SLC22A5 PROTEIN, MOUSE; SLC22A6 PROTEIN, MOUSE; SLC2A9 PROTEIN, MOUSE; STILBENE DERIVATIVE; TRANS 2,3',4,5' TETRAHYDROXYSTILBENE; TRANS 3,4' DIHYDROXY 2',3',5 TRIMETHOXYSTILBENE; TRANS-2,3',4,5'-TETRAHYDROXYSTILBENE; TRANS-3,4'-DIHYDROXY-2',3',5-TRIMETHOXYSTILBENE; URIC ACID;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HYPERURICEMIA; KIDNEY; MALE; METABOLISM; MOUSE; MOUSE STRAIN; PATHOPHYSIOLOGY; UREA NITROGEN BLOOD LEVEL; URINE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD UREA NITROGEN; CARRIER PROTEINS; CREATININE; DISACCHARIDES; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSIDES; GOUT SUPPRESSANTS; HYPERURICEMIA; KIDNEY; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED STRAINS; OCTAMER TRANSCRIPTION FACTOR-1; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; OXONIC ACID; STILBENES; URIC ACID;

MUS;

EID: 84865703695     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100828     Document Type: Article

References (45)

1. Choi, H. K., Curhan, G., Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116, 894-900.
2. Chonchol, M., Shlipak, M. G., Katz, R., Sarnak, M. J. et al., Relationship of uric acid with progression of kidney disease. Am. J. Kidney Dis. 2007, 50, 239-247.
3. Bhole, V., Choi, J. W., Kim, S. W., de Vera, M. et al., Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am. J. Med. 2010, 123, 957-961.
4. Preitner, F., Bonny, O., Laverriere, A., Rotman, S. et al., Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl. Acad. Sci. USA 2009, 106, 15501-15506.
5. Enomoto, A., Endou, H., Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin. Exp. Nephrol. 2005, 9, 195-205.
6. Woodward, O. M., Kottgen, A., Coresh, J., Boerwinkle, E. et al., Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. USA 2009, 106, 10338-10342.
7. Wang, B., Miao, Z., Liu, S., Wang, J. et al., Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population. Hum. Genet. 2010, 127, 245-246.
8. Hediger, M. A., Johnson, R. J., Miyazaki, H., Endou, H., Molecular physiology of urate transport. Physiology 2005, 20, 125-133.
9. Saito, H., Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Pharmacol. Therapeut. 2010, 125, 79-91.
10. Glube, N., Closs, E., Langguth, P., OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol. Pharm. 2007, 4, 160-168.
11. Grover, B., Buckley, D., Buckley, A. R., Cacini, W., Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J. Pharmacol. Exp. Ther. 2004, 308, 949-956.
12. Wang, C. P., Wang, Y., Wang, X., Zhang, X. et al., Mulberroside A possesses potent uricosuric and nephroprotective effects in hyperuricemic mice. Planta Med. 2011, 77, 786-794.
13. Dahan, K., Devuyst, O., Smaers, M., Vertommen, D. et al., A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J. Am. Soc. Nephrol. 2003, 14, 2883-2893.
14. Bachmann, S., Mutig, K., Bates, J., Welker, P. et al., Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. Am. J. Physiol. Renal Physiol. 2005, 288, F559-F567.
15. Bomalaski, J. S., Clark, M. A., Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr. Rheumatol. Rep. 2004, 6, 240-247.
16. Bardin, T., Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004, 71, 481-485.
17. Scott, E., Steward, W. P., Gescher, A. J., Brown, K., Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol. Nutr. Food Res. 2012, 56, 7-13.
18. Roupe, K. A., Remsberg, C. M., Yanez, J. A., Davies, N. M., Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 2006, 1, 81-101.
19. Smoliga, J. M., Baur, J. A., Hausenblas, H. A., Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55, 1129-1141.
20. Delmas, D., Aires, V., Limagne, E., Dutartre, P. et al., Transport, stability, and biological activity of resveratrol. Ann. NY Acad. Sci. 2011, 1215, 48-59.
21. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H. et al., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14, 612-622.
22. Brasnyó, P., Molnár, G. A., Mohás, M., Markó, L. et al., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106, 383-389.
23. Magyar, K., Halmosi, R., Palfi, A., Feher, G. et al., Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012, 50, 179-187.
24. Kondratyuk, T. P., Park, E. J., Marler, L. E., Ahn, S. Y. et al., Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol. Nutr. Food Res. 2011, 55, 1249-1265.
25. Matsuoka, A., Kodama, Y., Fukuhara, K., Honda, S. et al., A pilot study of evaluation of the antioxidative activity of resveratrol and its analogue in a 6-month feeding test in young adult mice. Food Chem. Toxicol. 2008, 46, 1125-1130.
26. Perecko, T., Jancinova, V., Drabikova, K., Nosal, R. et al., Structure-efficiency relationship in derivatives of stilbene. Comparison of resveratrol, pinosylvin and pterostilbene. Neuro. Endocrinol. Lett. 2008, 29, 802-805.
27. Paul, S., Rimando, A. M., Lee, H. J., Ji, Y. et al., Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev. Res. 2009, 2, 650-657.
28. Du, J., Sun, L. N., Xing, W. W., Huang, B. K. et al., Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine 2009, 16, 652-658.
29. Palsamy, P., Subramanian, S., Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed. Pharmacother. 2008, 62, 598-605.
30. Chen, L., Yin, H., Lan, Z., Ma, S. et al., Anti-hyperuricemic and nephroprotective effects of Smilax china L. J. Ethnopharmacol. 2011, 135, 399-405.
31. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A. et al., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-9011.
32. Ruiz, M. J., Fernandez, M., Pico, Y., Manes, J. et al., Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J. Agric. Food Chem. 2009, 57, 3180-3186.
33. Yao, J., Wang, J. Y., Liu, L., Zeng, W. S. et al., Polydatin ameliorates DSS-induced colitis in mice through inhibition of nuclear factor-kappaB activation. Planta Med. 2011, 77, 421-427.
34. Smoliga, J. M., Vang, O., Baur, J. A., Challenges of translating basic research into therapeutics: resveratrol as an example. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 158-167.
35. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A. et al., What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011, 6, e19881.
36. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 2008, 22, 659-661.
37. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. FDA 2005, 6-7. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf.
38. Williams, L. D., Burdock, G. A., Edwards, J. A., Beck, M. et al., Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem. Toxicol. 2009, 47, 2170-2182.
39. Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49, 472-481.
40. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudeux, J. L., Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16.
41. Zhaxi, M., Chen, L., Li, X., Komatsu, K. et al., Three major metabolites of mulberroside A in rat intestinal contents and feces. Planta Med. 2010, 76, 362-364.
42. Sovak, M., Grape extract, resveratrol, and its analogs: a review. J. Med. Food 2001, 4, 93-105.
43. Rimando, A. M., Kalt, W., Magee, J. B., Dewey, J. et al., Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J. Agric. Food Chem. 2004, 52, 4713-4719.
44. Kim, J. K., Kim, M., Cho, S. G., Kim, M. K. et al., Biotransformation of mulberroside A from Morus alba results in enhancement of tyrosinase inhibition. J. Ind. Microbiol. Biotechnol. 2010, 37, 631-637.
45. Sobolev, V. S., Khan, S. I., Tabanca, N., Wedge, D. E. et al., Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic stilbenoids. J. Agric. Food Chem. 2011, 59, 1673-1682.